Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

Vertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference ...

Vertex Pharmaceuticals (NASDAQ: VRTX ... I'm talking about suzetrigine for moderate-to-severe acute pain. Image source: Getty ...

CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved ... Image source: Getty Images. Several companies are using CRISPR to edit human genomes in an attempt to treat ...

The S&P 500 slipped 0.1% on Thursday, Dec. 19, 2024, as stocks struggled to recover from the prior day's sell-off despite upbeat data on economic growth.

Realistic Expectations for 10 Disruptive Technologies in 2025 The new year is here, and 2025 has the potential to be one of the most exciting moments in a long time. Momentum continues to build around ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...